These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 16965690)

  • 1. [Correlative analysis between serum dihydropyrimidine dehydrogenase, activity, concentration of 5-fluorouracil and adverse events in the treatment of advanced gastric cancer patients].
    Peng RJ; Dong QM; Shi YX; Cao Y; Zhou ZM; Yuan ZY; Li S; Li H; Jiang WQ
    Ai Zheng; 2006 Aug; 25(8):1039-43. PubMed ID: 16965690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
    Dong QM; He YJ; Li S; Zhou ZM; Zhang L; Zhou ZW; Xia ZJ; Li YY
    Ai Zheng; 2005 Apr; 24(4):483-7. PubMed ID: 15820075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
    Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
    Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer.
    Cho BC; Kim JH; Kim CB; Sohn JH; Choi HJ; Lee YC; Ahn JB
    Oncol Rep; 2006 Mar; 15(3):621-7. PubMed ID: 16465422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer].
    Feng JF; Lu JW; Sun XF
    Ai Zheng; 2004 Dec; 23(12):1704-6. PubMed ID: 15601565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
    Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
    Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale.
    Terashima M; Irinoda T; Kawamura H; Takagane A; Abe K; Oyama K; Fujiwara H; Saito K; Gotoh M; Shirasaka T
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):240-6. PubMed ID: 12655443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary report of semimonthly 5-fluorouracil/leucovorin combined with paclitaxel in treatment of advanced gastric cancer (AGC)].
    Zhou NN; Zhou ZM; Liu MZ; Li YH; Xu RH; Teng XY; Xiang XJ; Tian WH; Liu DG; Hu PL; Zhang B; Qiu HJ; Qian SY; He YJ
    Ai Zheng; 2003 Aug; 22(8):867-9. PubMed ID: 12917037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
    Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
    Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
    Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
    Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of two fluorouracil administration regimens for colorectal cancer.
    Matsusaka S; Yamasaki H; Kitayama Y; Okada T; Maeda S
    Oncol Rep; 2003; 10(1):109-13. PubMed ID: 12469154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
    Hisamitsu K; Tsujitani S; Yamaguchi K; Fukuda K; Konishi I; Kaibara N
    Anticancer Res; 2004; 24(4):2495-501. PubMed ID: 15330204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of oxaliplatin, fluorouracil and folinic acid (FOLFOX-6) as first-line chemotherapy in advanced or recurrent gastric cancer.
    Luo HY; Xu RH; Zhang L; Li YH; Shi YX; Lin TY; Han B; Wang F; Qiu MZ; He YJ; Guan ZZ
    Chemotherapy; 2008; 54(3):228-35. PubMed ID: 18560231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma.
    Kim R; Tanabe K; Inoue H; Toge T
    Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.